| Literature DB >> 23762780 |
Tian Yi Kang1, Hua Rong Yang, Jie Zhang, Dan Li, Jie Lin, Li Wang, Xiaoping Xu.
Abstract
Persistently increasing incident of cancer in human beings has served to emphasize the importance of studies on mechanism of antitumor substances. Chlorogenic acid (CA), extracted from folium cortex eucommiae, has been confirmed to have lots of biological activities encompassing inhibition of tumor. However, the anticancer mechanism of CA remains unclear. Here, we have utilized a whole mouse genome oligo microarray (4∗44K) to analyze gene expression level of female BALB/c mice (implanted with EMT-6 sarcoma cells) after treatment with low, medium, and high-dose CA (5 mg/kg, 10 mg/kg, and 20 mg/kg), docetaxel, interferon, and normal saline separately at 6 time points (3rd, 6th, 9th, 12th, 15th, and 18th days after administration). Differentially expressed genes screened out by time-series analysis, GO analysis, and pathway analysis, and four immune-related genes were selected for further confirmation using RT-qPCR. The results demonstrated that CA is able to change gene expression and that the responsive genes (CaN, NFATC2, NFATC2ip, and NFATC3) involved in immune pathways had been significantly upregulated by CA. Expression of immune factors such as IL-2R and IFN- γ can be improved by CA to promote activation and proliferation of T cells, macrophages, and NK cells, thus enhancing their surveillance and killing abilities, further suppressing the growth rate of tumor cells.Entities:
Year: 2013 PMID: 23762780 PMCID: PMC3665237 DOI: 10.1155/2013/617243
Source DB: PubMed Journal: J Anal Methods Chem ISSN: 2090-8873 Impact factor: 2.193
Primers used for RT-qPCR validation and additional expression profiling.
| Gene | GenBank accession | Forward | Reverse |
|---|---|---|---|
| Nfatc3 | NM_010901 | CTCCCTATCATAACCCA | CTgAAggCAAATCTgTG |
| Nfatc2ip | NM_010900 | AAAAgCAgAAAgCATACg | gACAggCCCTTCCACTA |
| Nfatc2 | NM_010899 | TgAgAAgATCgTAggCAAC | gCTCgATgTCAgCgTTT |
| CaN | NM_001004025 | TgggAAATgAggCgATT | CCACgCTCAAAgAACCAg |
Figure 1Expressing change of genes covered in NO.21 at 6 time points.
Pathways of upregulated genes.
| Pathway name | Hits | Total | Percent (%) |
|---|---|---|---|
| Natural killer cell mediated cytotoxicity— | 4 | 161 | 2.48 |
| B-cell receptor signaling pathway— | 5 | 85 | 5.88 |
| T-cell receptor signaling pathway— | 6 | 132 | 4.55 |
Upregulated genes in T-cell receptor signaling pathway, B-cell receptor signaling pathway, and natural killer cell mediated cytotoxicity.
| Pathway name | GeneID | ProbeID | Symbol |
|---|---|---|---|
| Natural killer cell mediated cytotoxicity— | 18019 | Nfatc2 | NFATC2 |
| 18021 | Nfatc3 | NFATC3 | |
| 19059 | CaN | CAN | |
| 22325 | Vav2 | VAV2 | |
|
| |||
| T-cell receptor signaling pathway— | 17973 | Nck1 | NCK1 |
| 56637 | Gsk3b | GSK3B | |
| 18019 | Nfatc2 | NFATC2 | |
| 18021 | Nfatc3 | NFATC3 | |
| 19059 | CaN | CAN | |
| 22325 | Vav2 | VAV2 | |
|
| |||
| B-cell receptor signaling pathway— | 56637 | Gsk3b | GSK3B |
| 18019 | Nfatc2 | NFATC2 | |
| 18021 | Nfatc3 | NFATC3 | |
| 19059 | CaN | CAN | |
| 22325 | Vav2 | VAV2 | |
GO of statistical significance.
| GO ID | Name | Hits | Total | Percent (%) |
|---|---|---|---|---|
| GO:0009055 | Electron carrier activity | 7 | 107 | 6.54 |
| GO:0003682 | Chromatin binding | 8 | 138 | 5.8 |
| GO:0046906 | Tetrapyrrole binding | 6 | 107 | 5.61 |
| GO:0030528 | Transcription regulator activity | 28 | 1053 | 2.66 |
| GO:0009058 | Biosynthetic process | 73 | 3388 | 2.15 |
| GO:0043167 | Ion binding | 78 | 3709 | 2.1 |
Immune related genes covered in GO and pathway.
| GenBank accession | GO ID | Gene symbol |
|---|---|---|
| NM_010899 | GO:0001816 | Nfatc2 |
| NM_010900 | GO:0001816 | Nfatc2ip |
| NM_010901 | GO:0003677 | Nfatc3 |
| NM_001004025 | GO:0004723 | CaN |
Relative expression level of target genes on average (, n = 10).
| Group | Gene | |||
|---|---|---|---|---|
| Nfatc2 | Nfatc3 | Nfatc2ip | CaN | |
| Docetaxel | 1.270 ± 1.216 | 1.311 ± 0.573 | 0.294 ± 0.160 | 1.136 ± 0.544 |
| Interferon | 3.831 ± 4.960 | 2.152 ± 1.089 | 0.562 ± 0.464 | 1.566 ± 0.914 |
| High-dose CA | 2.920 ± 2.047 | 4.341 ± 3.961 | 1.373 ± 1.096 | 1.961 ± 0.927 |
| Mid-dose CA | 1.086 ± 0.367 | 1.803 ± 1.255 | 0.937 ± 0.950 | 1.868 ± 1.160 |
| Low-dose CA | 1.185 ± 1.156 | 1.220 ± 1.303 | 0.507 ± 0.168 | 1.238 ± 0.310 |
| Negative | 1.085 ± 0.462 | 0.979 ± 0.839 | 0.769 ± 1.599 | 0.950 ± 0.418 |
Figure 2Relative expressing quantity of Nfatc2ip, Nfatc3, Nfatc2, and CaN in each groups. (a) Comparsion of Nfatc2ip expressing quantity among every group. (b) Comparsion of Nfatc3 expressing quantity among every group. (c) Comparsion of Nfatc2 expressing quantity among every group. (d) Comparsion of CaN expressing quantity among every groups.